BioSpace News Archive

Deals

ArriVent’s $175M Upsized IPO Builds Momentum on Heels of CG Oncology Offering

Late Thursday, ArriVent Biopharma announced its upsized initial public offering to support the development of its EGFR inhibitor furmonertinib, following CG Oncology going public earlier in the day.

January 26, 2024
·
2 min read
·
Tristan Manalac
Policy

Sanders Confident of Senate Panel’s Support for Subpoenaing J&J, Merck CEOs

Ahead of a Jan. 31 vote, Senate health committee chair Sen. Bernie Sanders on Thursday said he has the votes needed to subpoena the CEOs of Johnson & Johnson and Merck to testify on drug pricing.

January 26, 2024
·
2 min read
·
Tristan Manalac
Drug Development

CAR T Cell Conundrum: When Patients Develop New Cancers After Treatment

While the FDA continues to investigate reported cases of T cell malignancies in patients who received CAR-T therapies, the cause of the secondary cancers remains unclear.

January 26, 2024
·
3 min read
·
Greg Slabodkin
Business

Lonza Projects Flat Sales for 2024 as CDMOs Look to Recover from 2023

While the company expects sales growth to be flat this year, Lonza’s shares jumped around 14% Friday morning after reporting full-year 2023 sales of $7.75 billion, which was 3% above the consensus.

January 26, 2024
·
1 min read
·
Kate Goodwin
FDA

Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis

With the FDA’s approval on Thursday, Dupixent can now be used for the treatment of children aged 1 to 11 years who have eosinophilic esophagitis, a chronic disease that can severely impact their ability to eat.

January 26, 2024
·
2 min read
·
Tristan Manalac
Policy

Decoding the FDA’s Classifications for a Faster Path to Approval

The FDA’s myriad acronyms—and the differences between them—can be perplexing. BioSpace looks at the unique advantages of certain regulatory classifications for drug developers.

January 26, 2024
·
4 min read
·
Kate Goodwin
Medivir announces the outcome of the directed share issue which was announced on 22 January 2024

7,547,170 shares were issued, and all shares have been subscribed for by and allotted to Hallberg Management AB in accordance with the resolution regarding the share issue.

January 26, 2024
·
1 min read
Business

Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX

Tryp Therapeutics, Inc. today announced that in a strategic move to foster a robust market for their combined entity, Tryp and Exopharm Limited have been granted a pivotal 2 cent waiver by the Australian Securities Exchange (“ASX”).

January 26, 2024
·
5 min read
Pharvaris to Present at the WSAAI Annual Meeting 2024

Pharvaris today announced the acceptance of two abstracts for poster presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024, to be held from February 4-8, 2024, at the Grand Hyatt Kauai Resort & Spa in Koloa, Hawaii.

January 26, 2024
·
1 min read
Business

Covalon Announces Fourth Quarter and Year End Results for Fiscal 2023

Covalon Technologies Ltd. today announced its fiscal 2023 fourth quarter and year end results for the period ended September 30, 2023.

January 26, 2024
·
12 min read